Join us in San Francisco January 12-13 — in-person + online — early bird rates end soon
No images? Click here
How are we navigating biopharma's contradictions?
January 12 - 13, 2026 | 7:00 AM - 5:00 PM PT
Marriott Marquis, San Francisco
While everyone else waits for the market to turn, these executives are already making moves. Nothing is certain — except that deals continue to get done. What's in store for 2026?
ON THE AGENDA
AI, talent wars, and the biopharma workforce with Brent Saunders, Chairman & CEO of Bausch + Lomb
Taking stock of M&A with Eric Tokat, Co-President of Centerview Partners
Navigating organizational change with Tony Wood, Chief Scientific Officer of GSK
Featured conversation with Fred Ramsdell, Nobel laureate and Scientific Advisor
at Sonoma BiotherapeuticsFireside chat with Heather Turner, CEO of LB Pharmaceuticals Inc
Fireside chat with Frank Jiang, EVP and Chief Strategy Officer at Jiangsu Hengrui Pharmaceuticals
Join us to hear the conversations that shape how biopharma will move forward in this environment. Early bird pricing ends soon — secure your pass now before rates increase.
Early Bird in-person rates:
Save $200 on single passes
Save $900 on Group Passes
SPEAKERS
Tony Wood
Chief Scientific Officer
GSK
Heather Turner
CEO
LB Pharmaceuticals Inc
Frank Jiang
EVP, Chief Strategy Officer
Jiangsu Hengrui Pharmaceuticals
Brent Saunders
Chairman & CEO
Bausch + Lomb
Eric Tokat
Co-President
Centerview Partners
Fred Ramsdell
Nobel Laureate and Scientific Advisor
Sonoma Biotherapeutics
Endpoints at JPM26: Our journalists will dig into how companies are adjusting to regulatory uncertainty, scarce funding and China’s role in the new partnership landscape. Join us to find out what 2026 is shaping up to be.
Early bird pricing ends soon — secure your pass now before rates increase.
Can't make it to the Marriott Marquis? Virtual passes are available at no charge
EVENT SPONSORS
